PCI Pharma Services announces multi-million dollar expansion to UK manufacturing facility
pharmafile | July 27, 2022 | News story | Research and Development |
PCI has announced a significant expansion of its facility in Tredegar, Wales, UK, designed to help keep up to date with the market growth of powerful, targeted oncology therapies.
The expansion includes two new facilities dedicated to the manufacturing and packaging of solid-oral dose tablets and capsules. A second contained manufacturing building will double large-scale processing capacity, including dispensing and fluid bed granulation of high-potency solid-dose products at the commercial scale. There is also a new multi-product packaging facility with primary and secondary blistering and bottling suites.
“We’re excited to announce the latest expansion in Tredegar that will address the growing and urgent need for specialty global manufacturing services within the oncology arena,” said Salim Haffar, CEO, PCI Pharma Services. “As the market expands for potent therapies and highly complex, concentrated formulations that can present unique challenges to manufacturing and packaging, we’re proud to be one of the few providers with the global capabilities to manage this specialty at both clinical and importantly, commercial scale.”
“The rapid evolution of oncology pipelines has coincided with the continued globalization of clinical development,” said Rebecca Coutts, PhD, General Manager, Tredegar, PCI Pharma Services. “This latest investment, along with the existing analytical and formulation capabilities, combines a clinical and commercial scale packaging facility to complement the existing clinical and increased commercial scale manufacturing capabilities, placing end-to-end services for these high-potency molecules under one roof to better serve our client’s evolving needs.”
Lina Adams
